{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T08:14:13Z","timestamp":1770711253987,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T00:00:00Z","timestamp":1584576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1136\/annrheumdis-2019-216500","type":"journal-article","created":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T15:14:35Z","timestamp":1584630875000},"page":"490-498","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis"],"prefix":"10.1016","volume":"79","clinical-trial-number":[{"clinical-trial-number":"nct02065713","registry":"10.18810\/clinical-trials-gov","type":"results"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7170-8802","authenticated-orcid":false,"given":"Elsa","family":"Vieira-Sousa","sequence":"first","affiliation":[]},{"given":"Pedro","family":"Alves","sequence":"additional","affiliation":[]},{"given":"Ana M","family":"Rodrigues","sequence":"additional","affiliation":[]},{"given":"Filipa","family":"Teixeira","sequence":"additional","affiliation":[]},{"given":"Jose","family":"Tavares-Costa","sequence":"additional","affiliation":[]},{"given":"Alexandra","family":"Bernardo","sequence":"additional","affiliation":[]},{"given":"Sofia","family":"Pimenta","sequence":"additional","affiliation":[]},{"given":"Fernando M","family":"Pimentel-Santos","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o Lagoas","family":"Gomes","sequence":"additional","affiliation":[]},{"given":"Renata","family":"Aguiar","sequence":"additional","affiliation":[]},{"given":"Patr\u00edcia","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Taciana","family":"Videira","sequence":"additional","affiliation":[]},{"given":"Cristina","family":"Catita","sequence":"additional","affiliation":[]},{"given":"Helena","family":"Santos","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Borges","sequence":"additional","affiliation":[]},{"given":"Gra\u00e7a","family":"Sequeira","sequence":"additional","affiliation":[]},{"given":"C\u00e9lia","family":"Ribeiro","sequence":"additional","affiliation":[]},{"given":"L\u00eddia","family":"Teixeira","sequence":"additional","affiliation":[]},{"given":"Pedro","family":"\u00c1vila- Ribeiro","sequence":"additional","affiliation":[]},{"given":"Fernando M","family":"Martins","sequence":"additional","affiliation":[]},{"given":"Helena","family":"Canh\u00e3o","sequence":"additional","affiliation":[]},{"given":"Iain B.","family":"McInnes","sequence":"additional","affiliation":[]},{"given":"Ruy M","family":"Ribeiro","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o Eurico","family":"Fonseca","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1136\/annrheumdis-2019-216500_bib1","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2019-216500_bib2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41584-018-0147-9","article-title":"Pathophysiology, assessment and treatment of psoriatic dactylitis","volume":"15","author":"McGonagle","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/annrheumdis-2019-216500_bib3","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.3899\/jrheum.140879","article-title":"Comprehensive treatment of dactylitis in psoriatic arthritis","volume":"41","author":"Rose","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2019-216500_bib4","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/ard.2003.018184","article-title":"Dactylitis in psoriatic arthritis: a marker for disease severity?","volume":"64","author":"Brockbank","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2019-216500_bib5","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.3899\/jrheum.150165","article-title":"The Swedish early psoriatic arthritis registry 5-year followup: substantial radiographic progression mainly in men with high disease activity and development of Dactylitis","volume":"42","author":"Geijer","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2019-216500_bib6","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/acr.23249","article-title":"Clinical characteristics, disease activity, and patient-reported outcomes in psoriatic arthritis patients with Dactylitis or Enthesitis: results from the Corrona psoriatic Arthritis\/Spondyloarthritis registry","volume":"69","author":"Mease","year":"2017","journal-title":"Arthritis Care Res"},{"key":"10.1136\/annrheumdis-2019-216500_bib7","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/annrheumdis-2019-216500_bib8","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League against rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2019-216500_bib9","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.3899\/jrheum.140876","article-title":"Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic review","volume":"41","author":"Acosta Felquer","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2019-216500_bib10","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1136\/annrheumdis-2015-208466","article-title":"Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis","volume":"75","author":"Ramiro","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2019-216500_bib11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3899\/jrheum.120254","article-title":"Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the longterm extension of a randomized, placebo-controlled study (GO-REVEAL)","volume":"89","author":"Kavanaugh","year":"2012","journal-title":"J Rheumatol Suppl"},{"key":"10.1136\/annrheumdis-2019-216500_bib12","first-page":"80","article-title":"The GO-DACT protocol: a multicentre, randomized, double-blind, parallel-group study to compare the efficacy of golimumab in combination with methotrexate (MTX) versus MTX monotherapy","volume":"43","author":"Vieira-Sousa","year":"2018","journal-title":"Acta Reumatol Port"},{"key":"10.1136\/annrheumdis-2019-216500_bib13","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the impact 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2019-216500_bib14","first-page":"1745","article-title":"Development of an assessment tool for dactylitis in patients with psoriatic arthritis","volume":"32","author":"Helliwell","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2019-216500_bib15","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.23568","article-title":"Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis","volume":"59","author":"Healy","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2019-216500_bib16","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/ard.2007.084244","article-title":"Development and validation of the spondyloarthritis research Consortium of Canada (SPARCC) Enthesitis index","volume":"68","author":"Maksymowych","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2019-216500_bib17","series-title":"Eular Handbook of clinical assessments in rheumatoid arthritis","year":"2004"},{"key":"10.1136\/annrheumdis-2019-216500_bib18","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/rheumatology\/kem315","article-title":"MRI changes in psoriatic dactylitis\u2013extent of pathology, relationship to tenderness and correlation with clinical indices","volume":"47","author":"Healy","year":"2008","journal-title":"Rheumatology"},{"key":"10.1136\/annrheumdis-2019-216500_bib19","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.3899\/jrheum.090352","article-title":"The OMERACT psoriatic arthritis magnetic resonance imaging scoring system (PsAMRIS): definitions of key pathologies, suggested MRI sequences, and preliminary scoring system for PSA hands","volume":"36","author":"Ostergaard","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2019-216500_bib20","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.3899\/jrheum.141010","article-title":"Validation of the OMERACT psoriatic arthritis magnetic resonance imaging score (PsAMRIS) for the hand and foot in a randomized placebo-controlled trial","volume":"42","author":"Glinatsi","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2019-216500_bib21","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/art.34436","article-title":"Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial","volume":"64","author":"Kavanaugh","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2019-216500_bib22","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/acr.22204","article-title":"Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab","volume":"66","author":"Helliwell","year":"2014","journal-title":"Arthritis Care Res"},{"key":"10.1136\/annrheumdis-2019-216500_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/528105","article-title":"Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world","volume":"2014","author":"Salaffi","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1136\/annrheumdis-2019-216500_bib24","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2019-216500_bib25","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2019-216500_bib26","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1136\/annrheumdis-2017-211447","article-title":"How are enthesitis, dactylitis and nail involvement measured and reported in recent clinical trials of psoriatic arthritis? A systematic literature review","volume":"77","author":"Ramiro","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2019-216500_bib27","first-page":"1039","article-title":"Effectiveness of systemic treatment agents on psoriatic nails: a comparative study","volume":"12","author":"Demirsoy","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"10.1136\/annrheumdis-2019-216500_bib28","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/j.1468-3083.2010.03927.x","article-title":"Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study","volume":"25","author":"G\u00fcm\u00fc\u015fel","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1136\/annrheumdis-2019-216500_bib29","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/rheumatology\/ket426","article-title":"No overall damage progression despite persistent inflammation in adalimumab-treated psoriatic arthritis patients: results from an investigator-initiated 48-week comparative magnetic resonance imaging, computed tomography and radiography trial","volume":"53","author":"Poggenborg","year":"2014","journal-title":"Rheumatology"},{"key":"10.1136\/annrheumdis-2019-216500_bib30","unstructured":"Mease PJ, Gladman DD, Collier DH, et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase 3 trial. Arthritis Rheumatol."},{"key":"10.1136\/annrheumdis-2019-216500_bib31","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.3899\/jrheum.160420","article-title":"Five-Year safety data from 5 clinical trials of subcutaneous golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","volume":"43","author":"Kay","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2019-216500_bib32","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1136\/annrheumdis-2016-210775","article-title":"Anti-TNF-induced remission in very early peripheral spondyloarthritis: the CRESPA study","volume":"76","author":"Carron","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2019-216500_bib33","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3899\/jrheum.130163","article-title":"Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era","volume":"40","author":"Gladman","year":"2013","journal-title":"J Rheumatol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724014419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724014419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/annrheumdis-2019-216500","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T08:26:15Z","timestamp":1739521575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724014419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0003496724014419"],"URL":"https:\/\/doi.org\/10.1136\/annrheumdis-2019-216500","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2019-216500","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 \u00a9 Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}